REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On January6, 2017, REGENXBIO Inc. issued a press release (the
Press Release) regarding its operational highlights and financial
condition for the year ended December31, 2016. The final
subheading bullet of the Press Release and the first sentence of
the section titled 2017 Financial Guidance of the Press Release
are furnished as Exhibit 99.1 to this Current Report on Form 8-K
and incorporated herein by reference.

The information in Item2.02 of this Current Report on Form8-K,
and the final subheading bullet of the Press Release and the
first sentence of the section titled 2017 Financial Guidance of
the Press Release, shall not be deemed filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities of that
section, nor shall they be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

The Press Release also includes information regarding operational
highlights for the year ended December31, 2016 and certain
anticipated milestones and financial guidance for the year ending
December31, 2017.

A copy of the Press Release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated herein by reference,
with the exception of the final subheading bullet of the Press
Release and the first sentence of the section titled 2017
Financial Guidance of the Press Release, which are furnished as
set forth in Item2.02 above.